Skip to main content

Table 1 Clinical characteristics of the patients included in this study

From: PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study

 

Recurrence (n = 27)

Non-recurrence (n = 57)

p-value

Sex

  

0.64

 Male (%)

16 (59.3)

30 (52.6)

 

 Female (%)

11 (40.7)

27 (47.4)

 

Age (year)

  

0.95

 Median (range)

65 (38–79)

67 (40–80)

 

Pathological histotype

  

0.48

 Non poor (%)

18 (66.7)

33 (57.9)

 

 Poor (%)

9 (33.3)

24 (42.1)

 

Location

  

0.62

 Right (%)

7 (25.9)

19 (33.3)

 

 Left (%)

20 (74.1)

38 (66.7)

 

Depth

  

0.23

  < T4 (%)

20 (74.1)

49 (86.0)

 

  ≥ T4 (%)

7 (25.9)

8 (14.0)

 

Stage

  

0.14

 II (%)

5 (18.5)

4 (7.0)

 

 III (%)

22 (81.5)

53 (93.0)

 

Smoking status

  

0.64

 Brinkman index

   

  ≥ 400 (%)

12 (44.4)

22 (64.7)

 

  < 400 (%)

15 (55.6)

35 (70.0)

 

Alcoholic drinking

  

0.66

 Habitual drinkera (%)

1 (3.7)

5 (8.8)

 

 Non-habitual drinker (%)

26 (96.3)

52 (91.2)

 

Adjuvant regimen

  

0.72

 Oxaliplatin combinationb (%)

8 (38.1)

13 (61.9)

 

 Cape (%)

7 (24.1)

22 (75.9)

 

 S-1 (%)

7 (35.0)

13 (65.0)

 

 UFT + LV (%)

5 (35.7)

9 (64.3)

 
  1. In addition to sex, age, and life history, the high-risk factors for recurrence and regimens for Stage II colorectal cancer are also indicated. Fisher’s exact test was used to compare the recurrence and non-recurrence groups
  2. Cape capecitabine, UFT + LV oral uracil and tegafur (UFT) plus leucovorin (LV)
  3. aHabitual drinker: drinking > 60 g of ethanol per day
  4. bOxaliplatin combination: FOLFOX (5-FU, levofolinate, oxaliplatin):1, CAPOX (capecitabine, oxaliplatin):18, SOX (S-1, oxaliplatin):1
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us